Fintel reports that on December 15, 2025, Leerink Partners maintained coverage of Roivant Sciences (NasdaqGS:ROIV) with a Outperform recommendation. As of December 5, 2025, the average one-year price ...
Roivant Sciences (NASDAQ:ROIV) is gearing up to announce its quarterly earnings on Friday, 2026-02-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share. The trade increased direct holdings ...
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy ...
Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now. Following the company’s analyst meeting on December 11, Leerink Partners boosted its price target for Roivant ...
Roivant Sciences (ROIV) reported fiscal Q1 results and provided a pipeline update last week. Following RVT-3101’s strong results in ulcerative colitis patients, the focus shifts to the rest of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results